Arvee Laboratories (India) share news and announcements
NSE: ARVEEChemicals & PetrochemicalsSmall Cap
Last close ₹189.07down ₹8.31 (4.21%)
Share price at the NSE close on 23 Oct 2026. Previous close ₹197.38.
52-week range of traded prices to 23 Oct 2026
₹129.11Low, 30 Mar 2026₹290.78High, 19 Dec 2025
- Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 3 Nov 2026 to consider: financial results and other business matters.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹208 Cr2,476th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 7 Aug 2026
- 51.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 19 May 2026
- 6.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 7 Aug 2026
- 12.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Aug 2026
- 11.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 19 May 2026
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 1,57751.7% delivered
Arvee Laboratories (India) share news and announcements
259 announcements, routine notices left out, newest first. Page 4 of 6.
Jul 2021
Jun 2021
28 Jun · Related Party Transactions
21 Jun · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited for the quarter ended 31-Mar-2021 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.17 Jun · Updates
May 2021
27 May · Updates
Apr 2021
Mar 2021
30 Mar · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited with respect to announcement dated 26-Mar-2021, regarding sale of its entire investment in its wholly owned subsidiary Company namely Arvee Speciality Chemicals Private Limited.On basis of above the Company is required to clarify following: 1. The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;2. Date on which the agreement for sale has been entered into;3. The expected date of completion of sale/disposal;4. Brief details of buyers and whether any of the buyers belong to the promoter/ promoter group/group companies. If yes, details thereof.5. Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length";6. Additionally, in case of a slump sale, indicative disclosures provided for amalgamation/merger, shall be disclosed by the listed entity with respect to such slump sale.The response of the Company is awaited.
Feb 2021
15 Feb · Disclosure under SEBI (PIT) Reg 2015
Dec 2020
Nov 2020
12 Nov · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited for the quarter ended 30-Sep-2020 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Standalone Balance sheet statement not submitted -2. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.5 Nov · Board meeting
Oct 2020
26 Oct · Meeting
1 Oct · Board meeting
1 Oct · Corporate action
Sep 2020
Aug 2020
Jul 2020
Jun 2020
30 Jun · Legal
Exchange has sought clarification from Arvee Laboratories (India) Limited with respect to announcement dated 27-Jun-2020, regarding "Intimation of appointment of Mr PARAGBHAI MANUBHAI SHAH as Non- Executive Independent Director of the company w.e.f. Jun 27, 2020."On basis of above the Company is required to clarify following: 1. Brief profile (in case of appointment)The response of the Company is awaited.
May 2020